분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-05-07 08:21:39 , Hit : 1621
 Regeneron to Use Avalanche Platform in $640M+ Gene Therapy Collaboration


GEN News Highlights
More »
May 5, 2014

        Regeneron Pharmaceuticals will use Avalanche Biotechnologies’ adeno-associated virus (AAV)-based drug-delivery platform in a collaboration to commercialize its lead drug and new gene therapy products for ophthalmologic diseases, the companies said today. The collaboration could net Avalanche more than $640 million.

Under the collaboration, Regeneron will apply the Avalanche Ocular BioFactory™ to discover and develop gene therapy vectors for ophthalmology. BioFactory is designed to use the body's own cells to produce therapeutic protein after only a single injection. That in turn blocks VEGF signaling, treating the disease.

Avalanche says its platform reaches peak expression after 4-6 weeks, at which point the treatment can be maintained on an ongoing basis with a continuous, steady-state level of therapeutic protein, vs. a half-dozen or so re-injections a year with current treatments. Based on preclinical studies, Avalanche says the therapeutic effect from its lead product AVA-101 can be maintained for at least 18 months and has potential to last for several years following treatment from a single injection.

Regeneron agreed to pay Avalanche an undisclosed upfront cash payment, contingent payments of up to $640 million tied to development and regulatory milestones, plus a royalty on worldwide net sales of collaboration products.

The collaboration covers up to eight distinct therapeutic targets, with Regeneron holding exclusive worldwide rights for each product it moves forward in clinical development. Avalanche has the option to share in development costs and profits for products directed toward two collaboration therapeutic targets it will select.

Regeneron has a time-limited right of first negotiation for certain rights to AVA-101 upon completion of an ongoing Phase IIa trial. AVA-101 is Avalanche's gene therapy product targeting vascular endothelial growth factor (VEGF), now under development for the treatment of wet age-related macular degeneration (AMD).

"The collaboration will bring together Avalanche's novel platform technology with Regeneron's proprietary molecules and research capabilities, with the goal of creating a new class of next-generation biologics in ophthalmology,” Thomas W. Chalberg, Ph.D., Avalanche’s co-founder and CEO, said in a statement.

Avalanche’s collaboration with Regeneron comes almost two weeks after Avalanche completed a $55 million Series B financing intended to advance AVA-101 and other company clinical programs in retinal disorders. Avalanche said it will also use proceeds from the financing to invest in manufacturing and clinical infrastructure for AVA-101, as well as accelerate the development of pipeline programs based on the BioFactory platform.








707   암 미세환경의 저산소증으로 인한 PD-L1 의 발현  이성욱 2014/05/20 2428
706   단순 포진 바이러스 탑재 줄기세포로 악성 뇌종양 치료를?  이성욱 2014/05/19 2103
705   항체 생성은 위험 신호일 때만  이성욱 2014/05/19 1618
704   암 백신과 항체 치료의 항암 효과  이성욱 2014/05/19 2135
703   Top 100 Most Prescribed, Top Selling Drugs  이성욱 2014/05/15 3075
702   마우스에서 뇌종양의 성장을 조절하는 단백질 발견  이성욱 2014/05/14 1958
701   외계의` DNA를 가진 최초의 생명체 탄생  이성욱 2014/05/14 1870
700   항-EGFR 항체 치료의 저항성을 극복하는 새로운 대장암 치료제  이성욱 2014/05/13 2358
  Regeneron to Use Avalanche Platform in $640M+ Gene Therapy Collaboration  이성욱 2014/05/07 1621
698   인지과학의 수수께끼: 말(言)이 먼저일까, 생각이 먼저일까?  이성욱 2014/05/07 1646
697   DNA의 복사 기계가 일시 정지하는 경우, 암이 될 수 있어?  이성욱 2014/05/07 1771
696   실험쥐가 남성 연구자로부터 받는 스트레스?  이성욱 2014/05/02 2128
695   세계의 과학자들, 성인의 세포를 이용해 배아줄기세포를 만드는 데 잇달아 성공  이성욱 2014/04/30 1575
694   백신 개발을 위한 HIV의 취약 부위의 발견  이성욱 2014/04/30 1631
693   다운 증후군과 백혈병 사이의 연관성을 밝혀주는 연구 결과  이성욱 2014/04/24 2100
692   다시 뛰는 RNAi: 10억 달러 들여 신약 개발, 150가지 요법 임상시험  이성욱 2014/04/24 2793
691   Anti-viral regimen to treat adults with HCV awaits FDA approval  이성욱 2014/04/24 1439
690   Tales of Aptamer Selection: Astute Observation and Thoughtful Experimentation or Serendipity?  이성욱 2014/04/23 2500
689   암 줄기세포의 항암제 저항성과의 연관성  이성욱 2014/04/23 2316
688   CTLA-4 항체의 항암 효과를 높이는 새로운 혼합치료  이성욱 2014/04/21 2105

[이전 10개] [1]..[21][22][23][24][25][26][27][28] 29 [30]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN